Physician profile
Irina Gressel
NPI 1992727861
$2,716.86
in general payments reported to CMS, 2019-2025
31 companies · $397 in 2025
The $397 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $574 · 2020: $200 · 2021: $474 · 2022: $394 · 2023: $303 · 2024: $374 · 2025: $397.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,074.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,074.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $470.79 | 2021-2024 | |
| Astrazeneca Pharmaceuticals Lp | $385.21 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $348.05 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Abbvie INC. | $261.79 | 2021-2023 | |
| Pfizer INC. | $171.86 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $119.22 | 2019 | |
| Novo Nordisk INC | $115.10 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $99.57 | 2023-2024 | Rexulti |
| Global Blood Therapeutics, INC. | $83.02 | 2020-2021 | |
| Amgen INC. | $73.65 | 2025 | Repatha, Otezla |
| E.R. Squibb & Sons, L.L.C. | $68.32 | 2020-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $63.18 | 2024 | |
| Gilead Sciences, INC. | $56.31 | 2025 | |
| Supernus Pharmaceuticals, INC. | $35.89 | 2021-2022 | |
| Greenwich Biosciences, INC. | $34.25 | 2021 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $33.24 | 2019-2025 | Veozah |
| Amneal Pharmaceuticals LLC | $32.73 | 2023 | Rytary |
| Althera Pharmaceuticals LLC | $29.80 | 2021 | |
| Glaxosmithkline, LLC. | $26.11 | 2023 | Shingrix |
| Sanofi Pasteur INC. | $24.29 | 2019 | |
| Exact Sciences Corporation | $20.93 | 2025 | Cologuard Collection Kit |
| Vertical Pharmaceuticals, LLC | $19.59 | 2019 | |
| Lundbeck LLC | $19.42 | 2023 | Rexulti |
| Celgene Corporation | $18.91 | 2021 | |
| Biogen, INC. | $18.29 | 2022 | |
| Eisai INC. | $17.61 | 2019 | |
| Sunovion Pharmaceuticals INC. | $15.96 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.10 | 2019 | |
| Phadia US INC. | $13.18 | 2022 | |
| Jazz Pharmaceuticals INC. | $12.75 | 2022 | |
| Arbor Pharmaceuticals, INC. | $12.74 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Irina Gressel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.